Literature DB >> 12450548

Liquid chromatography-mass spectrometry method for the analysis of the anti-cancer agent capecitabine and its nucleoside metabolites in human plasma.

Yan Xu1, Jean L Grem.   

Abstract

A reversed-phase high-performance liquid chromatography method with electrospray ionization and mass spectral detection is described for the determination of capecitabine, 5'-deoxy-5-fluorocytidine and 5'-deoxy-5-fluorouridine in human plasma with 5-chloro-2'-deoxyuridine as the internal standard. An on-line sample clean-up procedure allows dilution of the plasma sample with the initial mobile phase. The linear dynamic range is 0.0500-10.0 microgram/ml for capecitabine, and 0.0500-25.0 microgram/ml for the metabolites, 5'-deoxy-5-fluorocytidine and 5'-deoxy-5-fluorouridine, respectively. This method has been used to analyze plasma samples from patients receiving capecitabine in combination with oxaliplatin.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12450548     DOI: 10.1016/s1570-0232(02)00674-8

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  6 in total

1.  The achievement of mass balance by simultaneous quantification of floxuridine prodrug, floxuridine, 5-fluorouracil, 5-dihydrouracil, α-fluoro-β-ureidopropionate, α-fluoro-β-alanine using LC-MS.

Authors:  Yasuhiro Tsume; Chester J Provoda; Gordon L Amidon
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2011-03-05       Impact factor: 3.205

2.  A tolerability and pharmacokinetic study of adjuvant erlotinib and capecitabine with concurrent radiation in resected pancreatic cancer.

Authors:  Wen Wee Ma; Joseph M Herman; Antonio Jimeno; Daniel Laheru; Wells A Messersmith; Christopher L Wolfgang; John L Cameron; Timothy M Pawlik; Ross C Donehower; Michelle A Rudek; Manuel Hidalgo
Journal:  Transl Oncol       Date:  2010-12-01       Impact factor: 4.243

3.  Thymidylate synthase (TYMS) enhancer region genotype-directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic cancer.

Authors:  Colin D Weekes; Sujatha Nallapareddy; Michelle A Rudek; Alexis Norris-Kirby; Daniel Laheru; Antonio Jimeno; Ross C Donehower; Kathleen M Murphy; Manuel Hidalgo; Sharyn D Baker; Wells A Messersmith
Journal:  Invest New Drugs       Date:  2010-03-23       Impact factor: 3.850

4.  Fixed-dose capecitabine is feasible: results from a pharmacokinetic and pharmacogenetic study in metastatic breast cancer.

Authors:  Michelle A Rudek; Roisin M Connolly; Janelle M Hoskins; Elizabeth Garrett-Mayer; Stacie C Jeter; Deborah K Armstrong; John H Fetting; Vered Stearns; Laurie A Wright; Ming Zhao; Stanley P Watkins; Howard L McLeod; Nancy E Davidson; Antonio C Wolff
Journal:  Breast Cancer Res Treat       Date:  2013-04-16       Impact factor: 4.872

5.  Use of capecitabine in management of early colon cancer.

Authors:  H Hameed; J Cassidy
Journal:  Cancer Manag Res       Date:  2011-08-19       Impact factor: 3.989

6.  A novel approach to the application of hexagonal mesoporous silica in solid-phase extraction of drugs.

Authors:  Fatemeh Farjadian; Soha Azadi; Soliman Mohammadi-Samani; Hajar Ashrafi; Amir Azadi
Journal:  Heliyon       Date:  2018-11-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.